首页> The Lancet. Global health> Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study.

Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Birahim Pierre,Ndiaye

第一单位： Institute for Health Research - Epidemiological Surveillance and Training, Dakar, Senegal.

作者： Birahim Pierre,Ndiaye ^[1] ; Lucy,Koech ^[2] ; Laina D,Mercer ^[3] ; John J,Aponte ^[4] ; Badara,Cisse ^[1] ; Faith,Riziki ^[2] ; Winnie,Keter ^[2] ; Niles,Eaton ^[3] ; Siry,Diye ^[1] ; Djibril,Wade ^[1] ; Ndeye Sakha,Bob ^[5] ; Mike G,Raine ^[3] ; Howard,Her ^[6] ; Sookyung,Kim ^[6] ; Rahsan,Erdem ^[3] ; Chankyu,Lee ^[6] ; Frederick J,Cassels ^[3] ; Youngran,Park ^[6] ; Moussa,Dia ^[5] ; Yeong Ok,Baik ^[6] ; Gamou,Fall ^[5] ; Emily,Locke ^[3] ; Patricia W,Njuguna ^[7]

作者单位： Institute for Health Research - Epidemiological Surveillance and Training, Dakar, Senegal. ^[1] Kenya Medical Research Institute-US Army Medical Research Directorate Africa-HJF Medical Research International, Kericho, Kenya. ^[2] PATH Center for Vaccine Innovation and Access, Seattle, WA, USA. ^[3] PATH Center for Vaccine Innovation and Access, Geneva, Switzerland. ^[4] Institut Pasteur de Dakar, Dakar, Senegal. ^[5] EuBiologics, Seoul, South Korea. ^[6] PATH Center for Vaccine Innovation and Access, Nairobi, Kenya. Electronic address: pnjuguna@path.org. ^[7]

医学主题词人类(Humans);塞内加尔(Senegal);肯尼亚(Kenya);女(雌)性(Female);男(雄)性(Male);成年人(Adult);婴儿(Infant);青少年(Adolescent);伤寒副伤寒菌苗(Typhoid-Paratyphoid Vaccines);青年人(Young Adult);儿童(Child);儿童, 学龄前(Child, Preschool);中年人(Middle Aged);伤寒(Typhoid Fever);单盲法(Single-Blind Method);疫苗, 结合(Vaccines, Conjugate)

DOI 10.1016/S2214-109X(25)00330-4

PMID 41240950

发布时间 2025-12-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The Lancet. Global health

2025年13卷12期

e2122-e2132页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

The Lancet. Global health

2025年13卷12期

e2122-e2132页

检索历史清除

Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study.

The Lancet. Global health

相似文献

同项目论文

The Lancet. Global health

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study.

The Lancet. Global health

相似文献

同项目论文

The Lancet. Global health

相关期刊

检索历史清除